Michael Berendt - Waters Independent Director
| WAT Stock | USD 388.15 9.99 2.64% |
Director
Dr. Michael Joseph Berendt, Ph.D., is Independent Director of Waters Corporationrationration. Since December 2016, Dr. Berendt was a life sciences industry consultant. From November 2013 to November 2016, Dr. Berendt was the Chief Executive Officer and Chief Scientist of Telesta Therapeutics. From July 2011 to November 2013, Dr. Berendt was a life sciences industry consultant. From March 2006 to July 2011, Dr. Berendt served as the President and Chief Executive Officer of Aegera Therapeutics Inc. From August 2004 to December 2005, Dr. Berendt served as Managing Director of Research Corporation Technologies, Inc. From November 2000 to August 2004, Dr. Berendt served as Managing Director of AEA Investors LP. Dr. Berendt also worked for 18 years, from 1982 to 2000, in the pharmaceutical industry where he served in a number of senior management positions including Senior Vice President of Research for the Pharmaceutical Division of Bayer Corporationrationration, and a Group Director of Drug Discovery at Pfizer, Inc since 1998.
| Age | 71 |
| Tenure | 26 years |
| Professional Marks | Ph.D |
| Address | 34 Maple Street, Milford, MA, United States, 01757 |
| Phone | 508 478 2000 |
| Web | https://www.waters.com |
Waters Management Efficiency
The company has Return on Asset of 0.1133 % which means that on every $100 spent on assets, it made $0.1133 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4964 %, implying that it generated $0.4964 on every 100 dollars invested. Waters' management efficiency ratios could be used to measure how well Waters manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.23 in 2024, whereas Return On Tangible Assets are likely to drop 0.14 in 2024. At this time, Waters' Non Current Liabilities Total is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 89.2 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 719.7 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Thomas Salice | Mettler Toledo International | 61 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Stephen Chubb | Charles River Laboratories | 76 | |
| Michael Kelly | Mettler Toledo International | 64 | |
| James Mullen | Thermo Fisher Scientific | 62 | |
| WahHui Chu | Mettler Toledo International | 69 | |
| John Danhakl | IQVIA Holdings | 64 | |
| Richard Reese | Charles River Laboratories | 75 | |
| A Sanders | Danaher | 58 | |
| James Fasano | IQVIA Holdings | 50 | |
| Scott Sperling | Thermo Fisher Scientific | 63 | |
| R Keith | Thermo Fisher Scientific | 52 | |
| Dion Weisler | Thermo Fisher Scientific | 53 | |
| Robert Bertolini | Charles River Laboratories | 59 | |
| Raymond Stevens | Danaher | 57 | |
| John Schwieters | Danaher | 81 | |
| Carol Burt | IQVIA Holdings | 62 | |
| Linda Filler | Danaher | 61 | |
| Debora Spar | Thermo Fisher Scientific | 56 | |
| John Connaughton | IQVIA Holdings | 54 | |
| Elias Zerhouni | Danaher | 69 | |
Management Performance
Waters Leadership Team
Elected by the shareholders, the Waters' board of directors comprises two types of representatives: Waters inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Waters. The board's role is to monitor Waters' management team and ensure that shareholders' interests are well served. Waters' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Waters' outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Lynch, Vice President Investor Relations | ||
| Gary Hendrickson, Independent Director | ||
| Edward Conard, Independent Director | ||
| Linda Baddour, Independent Director | ||
| JoAnn Reed, Advisor to CEO, Director and Member of Audit Committee | ||
| Flemming Ornskov, Independent Chairman of the Board | ||
| Christopher Kuebler, Independent Director | ||
| Christos Ross, Senior Operations | ||
| Michael Berendt, Independent Director | ||
| Kevin Kempskie, Director PR | ||
| Sherry Buck, Chief Financial Officer, Senior Vice President | ||
| Michael Silveira, Chief Financial Officer, Principal Accounting Officer | ||
| Belinda Hyde, Senior Vice President of Global Human Resources | ||
| Daniel Rush, Senior Transformation | ||
| Pearl Huang, Independent Director | ||
| Robert III, Senior Division | ||
| Patrick Conway, Interim Resources | ||
| Laurie Glimcher, Independent Director | ||
| Amol Chaubal, Chief Financial Officer, Senior Vice President | ||
| Christopher OConnell, Chairman of the Board, President, Chief Executive Officer | ||
| Jiang Wei, Director | ||
| Thomas Salice, Lead Independent Director | ||
| Udit Batra, President, Chief Executive Officer, Director | ||
| Michael Harrington, Senior Vice President - Global Markets | ||
| Ian King, Senior Vice President - Instrument Technology | ||
| Jonathan Pratt, Senior Vice President and President of TA Instruments | ||
| Caspar Tudor, Director Relations | ||
| Keeley JD, General VP | ||
| Robert Carson, Senior Vice President - Corporate Development | ||
| Dan Welch, Senior Vice President of Global Operations | ||
| Jianqing Bennett, VP Division | ||
| Kristen Garvey, Vice Communications | ||
| Elizabeth Rae, Senior Vice President - Global Human Resources | ||
| John Ballbach, Independent Director | ||
| Keeley Aleman, Senior Vice President General Counsel and Corporate Secretary |
Waters Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Waters a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | ||||
| Return On Asset | 0.11 | ||||
| Profit Margin | 0.21 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 24.62 B | ||||
| Shares Outstanding | 59.38 M | ||||
| Shares Owned By Institutions | 96.80 % | ||||
| Number Of Shares Shorted | 2.08 M | ||||
| Price To Earning | 40.43 X | ||||
| Price To Book | 14.38 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Waters Stock Analysis
When running Waters' price analysis, check to measure Waters' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Waters is operating at the current time. Most of Waters' value examination focuses on studying past and present price action to predict the probability of Waters' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Waters' price. Additionally, you may evaluate how the addition of Waters to your portfolios can decrease your overall portfolio volatility.